Artivion Inc
$ 45.42
-0.13%
04 Dec - close price
- Market Cap 2,154,612,000 USD
- Current Price $ 45.42
- High / Low $ 46.02 / 45.12
- Stock P/E N/A
- Book Value 9.26
- EPS -0.23
- Next Earning Report 2026-02-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE -0.02 %
- 52 Week High 48.04
- 52 Week Low 21.97
About
Artivion Inc. is a pioneering leader in the field of implantable human tissues and advanced medical devices, dedicated to enhancing surgical outcomes and improving patient care worldwide. With a strong focus on tissue bioengineering and regenerative medicine, the company is at the forefront of innovation, delivering high-quality solutions that meet the evolving demands of the healthcare sector. Artivion's commitment to continuous improvement and excellence positions it as a key player in the medical technology landscape, effectively addressing the pressing needs for sustainable and effective surgical interventions.
Analyst Target Price
$51.71
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-08 | 2025-05-05 | 2025-02-13 | 2024-11-07 | 2024-08-08 | 2024-05-06 | 2024-02-15 | 2023-11-02 | 2023-08-03 | 2023-05-04 | 2023-02-16 |
| Reported EPS | 0.16 | 0.03 | -0.012 | -0.3936 | -0.05 | -0.05 | 0.06 | -0.1 | -0.24 | -0.07 | -0.33 | 0.05 |
| Estimated EPS | 0.03 | -0.0033 | 0.045 | 0.0375 | -0.06 | -0.02 | -0.09 | -0.1 | -0.06 | -0.08 | -0.14 | -0.12 |
| Surprise | 0.13 | 0.0333 | -0.057 | -0.4311 | 0.01 | -0.03 | 0.15 | 0 | -0.18 | 0.01 | -0.19 | 0.17 |
| Surprise Percentage | 433.3333% | 1009.0909% | -126.6667% | -1149.6% | 16.6667% | -150% | 166.6667% | 0% | -300% | 12.5% | -135.7143% | 141.6667% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-12 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.07 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | None | None | None | None | None | None | None | None | None | None |
| Amount | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.03 | $0.0275 | $0.0275 | $0.0275 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AORT
2025-11-14 14:35:00
Artivion VP, Chief Accounting Officer Amy Horton sold 3,482 shares of company stock worth $159,677 to cover tax obligations from restricted stock unit vesting. This transaction followed positive Q3 2025 earnings for Artivion, which surpassed revenue and EPS forecasts, leading analysts at Oppenheimer and Needham to raise their price targets for the company. The raises reflect strong financial performance and growth prospects for Artivion.
2025-10-28 10:08:00
Artivion Inc. (AORT) stock has reached an all-time high of $45.1 USD, driven by robust performance, strong investor confidence, and positive clinical trial results for its AMDS Hybrid Prosthesis. Analyst price targets range from $38.8 to $50, with the company maintaining a "GOOD" financial position and expected profitability this year. Recent upgrades from several analyst firms further underscore the company's growth potential in the medical device sector.
2025-10-23 00:00:00
Artivion, Inc. announced that its third-quarter 2025 financial results will be released on Thursday, November 6, 2025, after market close. The company will host a teleconference call and live webcast at 4:30 p.m. ET on the same day to discuss the results, followed by a Q&A session with Chairman, President, and CEO Pat Mackin. Details for accessing the call, replay, and webcast are provided for investors.
2025-10-22 08:23:00
Artivion (AORT) recently announced positive data from its AMDS PERSEVERE and PROTECT clinical trials for its AMDS Hybrid Prosthesis, leading to increased investor optimism and share price momentum. The company is currently considered 6.5% undervalued with a narrative fair value above its latest close, despite its price-to-sales ratio being higher than industry averages. Investors are evaluating whether the market has already factored in its future growth, driven by strong revenue and EBITDA growth and the rising need for heart valve replacements.
2025-10-16 14:52:02
This article provides an AI-driven analysis of Artivion Inc Com (NASDAQ: AORT) stock, highlighting strong near-term sentiment while pointing towards mid-term neutrality and long-term positive bias. It presents three institutional trading strategies tailored to different risk profiles, along with multi-timeframe signal analysis and key findings such as a high risk-reward short setup. The analysis focuses on predictive AI insights for optimal positioning and risk management around price events.
2025-10-15 04:02:00
Despite a 78.2% surge in shares, this article advises caution with Artivion (AORT). The author outlines three reasons to sell AORT, including limited distribution channels, breakeven free cash flow, and unimpressive growth initiatives. The article suggests focusing on "High Quality" stocks instead, which have shown significant market-beating returns.
